Argo Wealth Advisory LLC Makes New $387,000 Investment in Pulse Biosciences, Inc $PLSE

Argo Wealth Advisory LLC acquired a new position in Pulse Biosciences, Inc (NASDAQ:PLSE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 28,156 shares of the company’s stock, valued at approximately $387,000.

Several other large investors have also made changes to their positions in the business. BNP Paribas Financial Markets raised its stake in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after purchasing an additional 680 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Pulse Biosciences by 44.0% in the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock valued at $79,000 after purchasing an additional 1,372 shares during the period. KLP Kapitalforvaltning AS increased its position in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after purchasing an additional 3,400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth about $158,000. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Stock Up 4.4%

Shares of PLSE stock opened at $20.51 on Friday. The stock has a market cap of $1.39 billion, a P/E ratio of -18.99 and a beta of 1.70. Pulse Biosciences, Inc has a fifty-two week low of $12.56 and a fifty-two week high of $26.30. The business has a fifty day simple moving average of $21.09 and a 200-day simple moving average of $17.27.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06.

Insider Activity at Pulse Biosciences

In related news, insider Kevin Patrick Danahy sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $23.64, for a total transaction of $118,200.00. Following the sale, the insider directly owned 43,298 shares in the company, valued at approximately $1,023,564.72. This trade represents a 10.35% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 85,000 shares of company stock worth $1,994,400. Company insiders own 74.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PLSE. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Mizuho set a $30.00 price objective on Pulse Biosciences in a research note on Friday, February 6th. Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 20th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pulse Biosciences presently has a consensus rating of “Hold” and a consensus target price of $30.00.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.